Our Unique Data
Historically, it had been difficult to obtain specific patient-level usage data in the
oncology marketplace because most of the products were administered directly by the
oncologist rather than dispensed through a pharmacy. Understanding the usage of a product
by specific diagnosis, line of therapy, stage of disease and regimen is now possible
by electronically harvesting oncology care information through IntrinsiQ's IntelliDose
clinical software.
Actual usage data confers a number of important advantages:
Actual clinical data, not survey data
Survey methodologies rely upon human recall for technical data streams. These methodologies are error prone when compared to actual clinical data.
Longitudinal view of physician and patient
By providing a patient and physician’s history over time, IntrinsiQ can determine length of therapy, interval length, switching characteristics, and identify practice patterns of physician “user” vs. “non-users”.
Unparalleled data quantity
With over 19,500 patients and over 135,000 drug administrations per month, the depth of the data is without compare. The quantity allows for analysis of tumors with smaller levels of patient incidence, and for analysis of latter lines of therapy where patient sampling can be difficult using other methods.
Swift turnaround time
IntrinsiQ’s data are transmitted electronically so there are no surveys to prepare and analyze. Our data is ready for viewing approximately twenty days after the end of a month. Some investigations can even be done on a weekly basis.
Our Research Offerings
IntrinsiQ Data Service
Available monthly online, IntrinsiQ is the only source for projected, regular, and complete data and analysis of US oncology practice behavior. Data from oncologists nation-wide is delivered with analysis enabling clients to size markets, forecast demand, and develop trial protocols.
IntrinsiQ Analytic Service
Customized analytics expands basic IntrinsiQ data to deliver more focused information. Deep dives into the data can concentrate on specific cancers, treatment paths, or event driven marketplace changes. Line of Treatment (LOT) analysis can be delivered as spreadsheet tools to reveal progression of specific treatments for tumor types. Findings can also be reported in presentations with charts, graphs, and executive analysis.
IntelliView 360
IntelliView 360™ is a joint offering from IntrinsiQ and WWMR. It links IntrinsiQ oncologist practice behavior with primary market research to bridge the gap between oncologist actions and opinions. IntelliView 360 panel members are the same oncologists that use IntrinsiQ IntelliDose to capture actual treatment data. Designed as an omnibus research service, IntelliView 360 provides an-hoc research at multi-client, cost-effective pricing and fast turnaround. Research waves are conveniently scheduled around major oncology conferences.